The FDA has approved Garzulys (insulin aspart-fsan), a biosimilar to NovoLog, for adults and children with diabetes mellitus, expanding access to rapid-acting insulin therapy in the U.S.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration has approved Garzulys™ (insulin aspart-fsan) injection, a biosimilar to NovoLog® (insulin aspart), for improving glycemic control in adults and children with diabetes mellitus. The rapid-acting human insulin analog is approved for both subcutaneous and intravenous administration, providing a new FDA-approved biosimilar option for patients requiring mealtime insulin therapy. The approval also marks an important milestone in Meitheal Pharmaceuticals’ expansion beyond generic injectable medicines into biologics and branded products.
Scientific and Clinical Context
Diabetes mellitus affects millions of patients worldwide and requires lifelong blood glucose management to reduce the risk of cardiovascular disease, kidney failure, neuropathy, retinopathy, and other complications. Rapid-acting insulin analogs such as insulin aspart control postprandial glucose by producing a faster onset of action than regular human insulin.
As an FDA-approved biosimilar, Garzulys demonstrated high similarity to the reference product, NovoLog, with no clinically meaningful differences in safety, purity, or potency, meeting the regulatory standards required for biosimilar approval. Increased availability of biosimilar insulin products may improve patient access while promoting competition in the U.S. insulin market.
Development and Regulatory Details
Garzulys was developed through a global collaboration involving Tonghua Dongbao Pharmaceutical Co., Ltd., Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), Xentria, Inc., Meitheal Pharmaceuticals, and Emerge Bioscience Pte. Ltd. Meitheal served as the U.S. regulatory agent during the FDA review, while Emerge holds the approved Biologics License Application (BLA).
Under their licensing agreement, Meitheal has exclusive U.S. commercialization rights for Garzulys. The partnership, established in 2023, also includes two additional insulin biosimilar candidates currently in development for the U.S. market.
Safety Profile
Garzulys is indicated for improving glycemic control in adults and pediatric patients with diabetes mellitus. Consistent with other insulin therapies, hypoglycemia remains the most frequently reported adverse reaction. The prescribing information also includes warnings regarding medication errors, severe hypersensitivity reactions, hypokalemia, fluid retention and heart failure when used with PPAR-gamma agonists, and hyperglycemia or ketoacidosis resulting from insulin pump malfunction. Common adverse reactions include allergic reactions, injection-site reactions, lipodystrophy, rash, and pruritus. Healthcare professionals should also monitor for clinically significant drug interactions that may alter glucose-lowering effects or mask symptoms of hypoglycemia.
Executive Perspective
Tom Shed, Chief Executive Officer of Meitheal Pharmaceuticals, said the FDA approval represents an important step in the company’s strategy to expand beyond its established generic injectable business into biologics and branded medicines. He noted that investments in regulatory capabilities, commercial infrastructure, and strategic partnerships have strengthened the company’s ability to execute complex global development programs while expanding access to biologic therapies.
Future Development
The approval broadens Meitheal’s diabetes portfolio and reinforces its strategy to expand its U.S. biologics business. The company now markets more than 80 FDA-approved products across multiple therapeutic areas, including oncology, anti-infectives, anesthesia, diabetes, critical care, and fertility.
Garzulys is expected to increase competition in the rapid-acting insulin market by offering an FDA-approved biosimilar alternative to NovoLog. The broader collaboration between Meitheal and Emerge, which includes two additional insulin biosimilars under development, suggests continued expansion of the company’s diabetes pipeline in the coming years.
Reference
Meitheal Pharmaceuticals Announces FDA Approval of Garzulys™ (insulin aspart-fsan) Injection
About the Writer
Chikkula Pavan Kumar (LinkedIn), PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.
